Related Experiment Video

Updated: Dec 8, 2025

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
07:30

Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression

Published on: June 15, 2019

10.4K

Targeting Complement C5a Receptor 1 for the Treatment of Immunosuppression in Sepsis

Oliver Sommerfeld1, Anna Medyukhina2, Sophie Neugebauer3

  • 1Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany; Center for Sepsis Control and Care (CSCC), Jena University Hospital, Jena, Germany.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|September 23, 2020
PubMed

Insights

Targeting complement factor C5a receptor 1 (C5ar1) improved survival in mild to moderate sepsis by enhancing pathogen clearance and immune responses. This suggests C5ar1 plays a role in sepsis-induced immunosuppression.

Area of Science:

  • Immunology
  • Inflammation Research
  • Sepsis Pathophysiology

Background:

  • Complement factor C5a (C5a) is known to promote inflammation via C5a receptor 1 (C5ar1).
  • Emerging evidence indicates C5a also mediates anti-inflammatory effects.
  • The precise role of C5ar1 in sepsis remains to be fully elucidated.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting C5ar1 in a murine model of sepsis.
  • To determine the impact of C5ar1 deficiency on sepsis outcomes and immune modulation.

Main Methods:

  • Utilized a murine sepsis model to compare wild-type and C5ar1-deficient mice.
  • Assessed survival rates, pathogen clearance, liver function, and cytokine profiles (interferon-γ and interleukin-10).

Main Results:

  • C5ar1-deficient mice showed significantly increased survival in mild to moderate sepsis, but not severe sepsis.
  • Improved pathogen clearance and preserved liver function were observed in C5ar1-deficient mice.
  • Deficiency in C5ar1 led to increased interferon-γ and decreased interleukin-10 production, altering the IFN-γ/IL-10 ratio.

Conclusions:

  • C5a signaling through C5ar1 mediates immunosuppressive processes during sepsis.
  • C5ar1 inhibition represents a potential therapeutic strategy for sepsis.
  • The C5ar1 and the IFN-γ/IL-10 ratio serve as markers for immune dysfunction in sepsis.
Keywords:
C5aR1homeostasishost responseinfectioninnate immunityintravital microscopyorgan dysfunctionsepsistheranotictherapeutic targets

More Related Videos

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies07:34

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

19.9K
Cecal Ligation Puncture Procedure11:53

Cecal Ligation Puncture Procedure

Published on: May 7, 2011

55.9K

Related Concept Videos

Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
7.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
341
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
358
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K